Depression, Bipolar & Mood Disorders • ICD-10-CM F29
Psychosis - atypical
Audited by the DotMD AI Specialist Council
•
FDA DailyMed SPL: 2026-11-02 • ICD-10-CM F29 • 8 Linked .gov / PubMed Citations
•
Governance: Dr. Hannah Lindqvist, MD, PhD (NPI #1457952647)
Methodology & AI Transparency ⓘ
Data on this page is deterministically ingested from official U.S. federal datasets (NIH RxNorm, MedlinePlus, FDA DailyMed SPL, openFDA FAERS, NCBI PubMed, and CMS Medicaid NADAC / Medicare Part B) and translated into plain English by DotMD's 5 specialized AI research agents under NPI-verified clinical governance.
At a Glance • Plain-English Clinical Summary
Psychosis - atypical Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within Depression, Bipolar & Mood Disorders practice, Psychosis - atypical (ICD-10 F29) is stratified through medication response pharmacogenomics [Psychosis - atypical F29], pairing targeted symptom control with longitudinal Serum Vitamin D in Psychosis - atypical (F29: & RBC Folate) surveillance.
- 2 Real-world patient consensus: Federal ICD-10-CM code F29 categorizes Psychosis - atypical under Depression, Bipolar & Mood Disorders.
- 3 Typical cash cost range: Workup highlights for Psychosis - atypical (F29): medication response pharmacogenomics [Psychosis - atypical F29].
- 4 Top reported side effects / signs: Follow-up benchmark in Psychosis - atypical: maintaining TSH & Free in Psychosis - atypical (F29: T4 Rule-Out) within TSH 0.8 – 2.5 mIU/L (F29).
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data
3 of 3 Free Questions RemainingAsk our AI Specialists anything about Psychosis - atypical
What Is Psychosis - atypical?
Within Depression, Bipolar & Mood Disorders practice, Psychosis - atypical (ICD-10 F29) is stratified through medication response pharmacogenomics [Psychosis - atypical F29], pairing targeted symptom control with longitudinal Serum Vitamin D in Psychosis - atypical (F29: & RBC Folate) surveillance.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Psychosis - atypical (code F29) is monoaminergic (serotonin [Psychosis - atypical F29], which Depression, Bipolar & Mood Disorders clinicians address while surveilling TSH & Free in Psychosis - atypical (F29: T4 Rule-Out) (TSH 0.8 – 2.5 mIU/L (F29)).
Common Symptoms & Clinical Signs
- • Presentation of Psychosis - atypical (F29): loss of interest in Psychosis - atypical (F29: or pleasure in)
- • Secondary Psychosis - atypical clinical sign: persistent low mood, in Psychosis - atypical (F29: emotional flatness, or)
- • Symptom flares in Psychosis - atypical correlating with TSH & Free in Psychosis - atypical (F29: T4 Rule-Out) deviation outside TSH 0.8 – 2.5 mIU/L (F29)
- • Functional depression & mood impact requiring medication response pharmacogenomics [Psychosis - atypical F29] evaluation (F29)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Psychosis - atypical Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F29 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Depression, Bipolar & Mood Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: TSH & Free in Psychosis - atypical (F29: T4 Rule-Out) | TSH 0.8 – 2.5 mIU/L (F29) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Vitamin D in Psychosis - atypical (F29: & RBC Folate) | 25(OH)D 40 – 65 ng/mL (F29) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: PHQ-9 Symptom Severity in Psychosis - atypical (F29: Score) | < 4 (clinical remission) (F29) | Clinical Reference Target Range |
Marcus Sterling (AI Healthcare Price Auditor) & Dr. Vance
Check Drug Interactions →
FDA-Monographed Medications & Public Cash Price Reference for Psychosis - atypical
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Quetiapine Fumarate Seroquel • RxCUI 312743 | Atypical Antipsychotic | 92% | $0.0209 | $ 5.35 /mo |
| Clozaril (Clozapine) Clozaril • RxCUI 104775 | Atypical Antipsychotic | 94% | $6.2959 | $ 461.80 /mo |
| Asenapine Secuado, Saphris • RxCUI 859975 | Atypical Antipsychotic | 94% | $2.3627 | $ 57.01 /mo |
| Cariprazine Vraylar • RxCUI RXN-61874130-2392 | Atypical Antipsychotic | 88% | $48.5295 | $ 185.00 /mo |
| Vraylar (Cariprazine) Vraylar • RxCUI RXN-B61874130 | Atypical Antipsychotic | 94% | $48.5295 | $ 640.00 /mo |
| Lybalvi (Olanzapine and Samidorphan L-Malate) Lybalvi • RxCUI 2570398 | Atypical Antipsychotic | 81% | $52.5028 | $ 640.00 /mo |
| Risperidone Risperdal Consta, Risperdal • RxCUI 312830 | Atypical Antipsychotic | 87% | $0.0358 | $ 5.36 /mo |
| Latuda (Lurasidone Hydrochloride) Latuda • RxCUI 1040036 | Atypical Antipsychotic | 80% | $45.3287 | $ 7.45 /mo |
| Olanzapine and Fluoxetine (Olanzapine and Fuoxetine) Olanzapine and Fluoxetine • RxCUI 403970 | Atypical Antipsychotic | 85% | $4.0280 | $ 298.52 /mo |
| Saphris (Asenapine Maleate) Saphris • RxCUI 1606337-B04562410 | Atypical Antipsychotic | 93% | $20.1874 | $ 57.01 /mo |
| Olanzapine Pamoate Zyprexa Relprevv, Zyprexa • RxCUI 1718925 | FDA Prescription Therapeutic Agent | 79% | $0.1069 | $ 12.83 /mo |
| Risperdal (Risperidone) Risperdal • RxCUI 312828-B50458330 | Atypical Antipsychotic | 82% | $9.1619 | $ 5.36 /mo |
| Seroquel XR (Quetiapine) Seroquel XR • RxCUI 721791 | Atypical Antipsychotic | 93% | $14.1432 | $ 7.14 /mo |
| Ziprasidone Hydrochloride (Ziprasidone HCl) Ziprasidone Hydrochloride • RxCUI 313776 | Atypical Antipsychotic | 75% | $0.2181 | $ 24.20 /mo |
| Rexulti (Brexpiprazole) Rexulti • RxCUI RXN-B59148036 | Atypical Antipsychotic | 89% | $48.3704 | $ 640.00 /mo |
| Paliperidone Invega • RxCUI 672567 | Atypical Antipsychotic | 93% | $1.0186 | $ 49.75 /mo |
Dr. Lin (AI PubMed Clinical Trial Lead)
Browse All PubMed Translations →
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Psychosis - atypical)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Normalization of EEG in depression after antidepressant treatment with: What a 1,008-Participant Study Found Response rates in patients with normalized EEG taking sertraline were significantly larger than in subjects treated with escitalopram/venlafaxine. Journal of affective disorders • 2019-12-01 • Randomized Controlled Trial | N = 1,008 | 90/100 | PMID 31437703 ↗ |
| Can This Approach Help? Inside the Latest Research on Real-world benefits and safety of adding celecoxib to escitalopram for improving Adding celecoxib to escitalopram may improve symptoms of depression in patients with depression without increasing the risk of drug-related side effects. International journal of psychiatry in medicine • 2024-09-15 • Randomized Controlled Trial | N = 60 | 88/100 | PMID 38116669 ↗ |
| Can This Approach Help? Inside the Latest Research on Safety and real-world benefits of pimavanserin in patients with Lewy body Psychosis relapse risk was significantly lower with pimavanserin vs. BMC neurology • 2025-11-24 • Phase III Randomized Trial | N = 22 | 88/100 | PMID 41286676 ↗ |
| Can This Approach Help? Inside the Latest Research on Trial of sertraline versus venlafaxine XR in major depression: efficacy and Sertraline and venlafaxine XR demonstrated comparable effects on QOL and efficacy in treatment of major depression, although sertraline may be associated with a lower symptom burden during treatment discontinuation and a... The Journal of clinical psychiatry • 2005-10-15 • Randomized Controlled Trial | N = 163 | 88/100 | PMID 16259546 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy of Transdermal Estradiol and Micronized Progesterone in the Prevention Twelve months of TE+IMP were more effective than placebo in preventing the development of clinically significant depressive symptoms among initially euthymic perimenopausal and early postmenopausal women. JAMA psychiatry • 2018-02-01 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 29322164 ↗ |
Zero-PHI Patient Support & Cohort Discussions
Psychosis - atypical Patient Community & “People Like Me” Threads
“People Like Me” Cohort Filter (Zero-PHI)
Filter Psychosis - atypical community threads and patient logs by age, biological sex, dosage, and treatment duration.
No threads match this cohort filter yet. Click + Start Anonymous Discussion to ask the community about Psychosis - atypical.